NCT Number: NCT00139087
Mother-Infant Rapid Intervention at Delivery Telephone Outreach for Neonatal Therapy (TOT) Trial.
The Telephone Outreach for Therapy Trial was designed to test an intervention to assist new mothers or caregivers of HIV-exposed children with administering medication for the first 6 weeks of life to prevent mother-to-child HIV infection in the infants. To be eligible, mothers of infants were identified as HIV-infected in the Mother-Infant Rapid Intervention at Delivery Study. Mothers or caregivers of infants were randomized into two groups: the intervention group received a cellular phone and scheduled twice daily calls to assure infant medications were given, and the other group received the current standard of care. Enrollment into the study was completed and analysis of the study data is underway.
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 hour–2 week
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
The Telephone Outreach for Therapy Trial was designed to test an intervention to assist new mothers or caregivers of HIV-exposed children with administering medication for the first 6 weeks of life to prevent mother-to-child HIV infection in the infants. To be eligible, mothers of infants were identified as HIV-infected in the Mother-Infant Rapid Intervention at Delivery Study. Mothers or caregivers of infants were randomized into two groups: the intervention group received a cellular phone and scheduled twice daily calls to assure infant medications were given, and the other group received the current standard of care. Enrollment into the study was completed and analysis of the study data is underway.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Mother-infant pairs in which the mother was identified as HIV-infected in the MIRIAD Study
Exclusion criteria
- Mother-infant pairs in which the infant is expected to be hospitalized for >2weeks after birth
Treatment and study plan
Primary outcomes
-
Neonatal adherence to zidovudine syrup measured as self report of the mother or caregiver AND drug level measured in heel stick specimens collected at 2, 4 and 6 weeks of life.
Sponsors and collaborators
Lead sponsor
Centers for Disease Control and Prevention
Fed
Registry information
Important dates
- Study start
- 2002
- Study completion
- 2005
- First posted
- Aug 31, 2005
- Registry last updated
- Aug 31, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Single Session Narrative Therapy Study
NCT06479980
Chemically-Induced Disorders, HIV
Seattle, Washington, United States
View Trial DetailsTissue Biopsy and Imaging Studies in HIV-Infected Patients
NCT00001471
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Bethesda, Maryland, United States
View Trial DetailsHOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
NCT03500315
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial DetailsTesting a Community-Friendly Risk Reduction Intervention for Injection Drug Users
NCT01741350
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial Details